Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers
Phase 1
- Conditions
- Anticoagulant
- Interventions
- Drug: Lixiana(D006)Drug: CKD-344
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 60
- Registration Number
- NCT04867200
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Korea, Republic of
Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 112
- Registration Number
- NCT04867720
- Locations
- 🇰🇷
Seoul National University Hosipital, Seoul, Korea, Republic of
A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
Phase 3
Completed
- Conditions
- Neovascular(Wet) Age Related Macular Degeneration
- Interventions
- Drug: CKD-701Drug: Lucentis®
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 312
- Registration Number
- NCT04857177
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1
Phase 1
- Conditions
- Early Puberty
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT04840745
- Locations
- 🇰🇷
Severance Hospital, Seoul, Yonsei-ro, Seodaemun-gu 50-1, Korea, Republic of
A Study to Investigate the Effect of Food on the PK, PD of CKD-381 in Healthy Volunteers
Phase 1
Completed
- Conditions
- GERD
- Interventions
- Drug: CKD-381
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT04830930
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.
Phase 1
Completed
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- Drug: CKD-501, D745, D150Drug: CKD-383
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 27
- Registration Number
- NCT04810676
- Locations
- 🇰🇷
Severance Hospital, Seoul, Yonsei-ro, Seodaemun-gu 50-1, Korea, Republic of
A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843
Phase 1
Completed
- Conditions
- Alopecia
- Interventions
- Drug: CKD-843 ADrug: CKD-843 BDrug: CKD-843-R
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 40
- Registration Number
- NCT04805606
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
A Study to Investigate the PK and Safety of CKD-393
Phase 1
Completed
- Conditions
- Type II Diabetes
- Interventions
- Drug: CKD-393 formulation IDrug: CKD-393 formulation IIDrug: D501, D759, H053
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 26
- Registration Number
- NCT04768673
- Locations
- 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu,, Korea, Republic of
Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: CKD-510 multiple doseDrug: CKD-510 single doseDrug: CKD-510 food effectDrug: Placebo
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 87
- Registration Number
- NCT04746287
- Locations
- 🇫🇷
Clinical site, Grenoble, France
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
Phase 1
- Conditions
- T2DM (Type 2 Diabetes Mellitus)
- Interventions
- Drug: CKD-501, D759, D150Drug: CKD-393 0.5/100/1000 mg
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 26
- Registration Number
- NCT04706286
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath